Kamal Patel, MD
Hematology & Oncology · Little Rock, ARNPI 1598747164
Payments from drug & device makers
Across 163 payments — averaging $4271.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$380K
- Pfizer$131K
- Helsinn Healthcare SA$119K
- Takeda Pharmaceuticals U.S.A., Inc.$46K
- AbbVie$11K
- Bristol Myers Squibb$8K
- plus $1K from 17 others
Across 10 payments — averaging $1661.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$17K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 74 | $380,304 |
| Pfizer | 27 | $130,626 |
| Helsinn Healthcare SA | 15 | $119,290 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $45,738 |
| AbbVie | 1 | $11,345 |
| Bristol Myers Squibb | 7 | $7,955 |
| Kyowa Kirin, Inc. | 3 | $195 |
| Seagen Inc. | 5 | $132 |
| Johnson & Johnson | 3 | $127 |
| Astellas Pharma US Inc | 2 | $109 |
| Sirtex Medical Inc | 1 | $103 |
| Regeneron Healthcare Solutions, Inc. | 1 | $98 |
| Eisai Inc. | 4 | $70 |
| AstraZeneca | 2 | $47 |
| Sanofi | 2 | $33 |
| Acrotech Biopharma Inc. | 2 | $26 |
| Blueprint Medicines Corporation | 1 | $21 |
| Beone Medicines USA, Inc. | 1 | $20 |
| Daiichi Sankyo Inc. | 1 | $20 |
| Foundation Medicine, Inc. | 1 | $14 |
| Gilead | 1 | $12 |
| Epizyme, Inc. | 1 | $12 |
| Bayer | 1 | $11 |
How this compares
$696,307 in reported general payments places this provider in the 90th percentile of 92 hematology & oncology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Little Rock
- Ryan HallLittle Rock$4.1M
- Issam MakhoulLittle Rock$3.4M
- Carolina SchinkeLittle Rock$932K
- Frits van RheeLittle Rock$789K
- Rhonda GentryLittle Rock$328K
- Appalanaidu SasapuLittle Rock$313K
- Joseph BeckLittle Rock$261K
- Pooja MotwaniLittle Rock$222K
- David KupermanLittle Rock$187K
- Brad BaltzLittle Rock$106K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.